{"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"groups":[{"description":"SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.","id":"BG000","title":"SyB L-0501 + Prednisolone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"2.3","value":"69.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEDIAN","title":"Age Continuous","unitOfMeasure":"Year"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"20-29 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"30-39 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"40-49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"60-69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"70-84 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Yes"}],"description":"Condition with symptoms of Multiple Myeloma (Development of hyperviscosity syndrome, amyloidosis, Bacterial infection twice or more in a year)","paramType":"NUMBER","title":"Condition with symptoms of Multiple Myeloma","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Yes"}],"paramType":"NUMBER","title":"Previous treatment of multiple myeloma","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Age 66 years or older"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Presence of cardiopulmonary dysfunction"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Renal dysfunction"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Reason for not eligible for hematopoietic stem cell transplantation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"3"}],"description":"0: Asymptomatic 1: Symptomatic but completely ambulatory 2: Symptomatic, \\<50% in bed during the day 3: Symptomatic, \\>50% in bed, but not bedbound","paramType":"NUMBER","title":"Performance status (P.S.)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Stage III"}],"description":"Stage I: Serum β2-microglobulin (β2M) \\< 3.5 mg/L and serum albumin ≥ 3.5 g/dL)\n\nStage II: Serum β2M ≥3.5 - \\< 5.5 mg/L; or serum β2M \\< 3.5 mg/L and serum albumin \\< 3.5 g/dL)\n\nStage III: (Serum β2M ≥ 5.5 mg/L)","paramType":"NUMBER","title":"Clinical stage [International staging system (ISS) category]","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Yes"}],"paramType":"NUMBER","title":"Previous history of multiple myeloma","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Yes"}],"paramType":"NUMBER","title":"Associated symptom of the primary disease","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Yes"}],"paramType":"NUMBER","title":"Complications of multiple myeloma","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1.48","value":"5.00"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEDIAN","title":"Serum β2M in clinical stage","unitOfMeasure":"mg/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.53","value":"151.40"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.41","value":"52.40"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEDIAN","title":"Weight","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.185","value":"1.470"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEDIAN","title":"Body surface area","unitOfMeasure":"m2"}]}